Pfizer [PFIZER] vs Concord Biotech [CONCORDBIO] Detailed Stock Comparison

Pfizer

NSE
Loading...

Concord Biotech

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Pfizer wins in 15 metrics, Concord Biotech wins in 5 metrics, with 0 ties. Pfizer appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricPfizerConcord BiotechBetter
P/E Ratio (TTM)29.1548.78Pfizer
Price-to-Book Ratio5.559.57Pfizer
Debt-to-Equity Ratio2.570.16Concord Biotech
PEG Ratio1.07-1.87Concord Biotech
EV/EBITDA28.0835.30Pfizer
Profit Margin (TTM)34.83%29.97%Pfizer
Operating Margin (TTM)32.44%21.38%Pfizer
EBITDA Margin (TTM)32.44%21.38%Pfizer
Return on Equity18.20%20.50%Concord Biotech
Return on Assets (TTM)15.63%18.27%Concord Biotech
Free Cash Flow (TTM)$6.32B$1.33BPfizer
Dividend Yield1.27%0.44%Pfizer
1-Year Return-15.59%-22.53%Pfizer
Price-to-Sales Ratio (TTM)10.1614.59Pfizer
Enterprise Value$207.39B$170.33BPfizer
EV/Revenue Ratio8.9314.33Pfizer
Gross Profit Margin (TTM)64.97%77.89%Concord Biotech
Revenue per Share (TTM)$507$114Pfizer
Earnings per Share (Diluted)$175.55$33.98Pfizer
Beta (Stock Volatility)0.120.95Pfizer
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Pfizer vs Concord Biotech Stock Performance Analysis

Loading Price Chart...

Pfizer
Concord Biotech
Pfizer Stock Overview | Concord Biotech Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pfizer0.49%0.16%3.00%-8.30%23.98%-3.10%
Concord Biotech-2.83%-4.45%0.80%-19.98%-3.95%-25.04%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pfizer-15.59%23.38%3.12%100.33%365.85%558.28%
Concord Biotech-22.53%70.85%70.85%70.85%70.85%70.85%

News Based Sentiment: Pfizer vs Concord Biotech

Pfizer

News based Sentiment: POSITIVE

Pfizer Ltd. delivered strong financial results in Q1 FY26, coupled with a strategic partnership to boost healthcare innovation in India and a positive analyst rating. These developments signal a positive trajectory for the company and strengthen its investment case, making it a significant month for investors.

View Pfizer News Sentiment Analysis

Concord Biotech

News based Sentiment: MIXED

Concord Biotech experienced a revenue decline in Q1 FY26 but demonstrated strong profit growth and achieved a successful EU GMP inspection. The increased dividend signals confidence, but the slight share price decrease and shifting institutional holdings introduce some uncertainty, resulting in a mixed overall investment story.

View Concord Biotech News Sentiment Analysis

Performance & Financial Health Analysis: Pfizer vs Concord Biotech

MetricPFIZERCONCORDBIO
Market Information
Market Cap i₹237.81B₹173.68B
Market Cap CategoryLarge capMid cap
10 Day Avg. Volume i22,26189,767
90 Day Avg. Volume i49,780116,021
Last Close₹5,143.00₹1,610.80
52 Week Range₹3,701.00 - ₹6,326.15₹1,345.00 - ₹2,664.00
% from 52W High-18.70%-39.53%
All-Time High₹6,451.15 (Sep 02, 2024)₹2,664.00 (Sep 16, 2024)
% from All-Time High-20.28%-39.53%
Growth Metrics
Quarterly Revenue Growth0.07%-0.06%
Quarterly Earnings Growth0.27%-0.26%
Financial Health
Profit Margin (TTM) i0.35%0.30%
Operating Margin (TTM) i0.32%0.21%
Return on Equity (TTM) i0.18%0.21%
Debt to Equity (MRQ) i2.570.16
Cash & Liquidity
Book Value per Share (MRQ)₹921.88₹173.28
Cash per Share (MRQ)₹608.26₹30.36
Operating Cash Flow (TTM) i₹9.08B₹2.98B
Levered Free Cash Flow (TTM) i₹7.68B₹3.72B
Dividends
Last 12-Month Dividend Yield i1.27%0.44%
Last 12-Month Dividend i₹70.00₹8.75

Valuation & Enterprise Metrics Analysis: Pfizer vs Concord Biotech

MetricPFIZERCONCORDBIO
Price Ratios
P/E Ratio (TTM) i29.1548.78
Forward P/E i30.5733.42
PEG Ratio i1.07-1.87
Price to Sales (TTM) i10.1614.59
Price to Book (MRQ) i5.559.57
Market Capitalization
Market Capitalization i₹237.81B₹173.68B
Enterprise Value i₹207.39B₹170.33B
Enterprise Value Metrics
Enterprise to Revenue i8.9314.33
Enterprise to EBITDA i28.0835.30
Risk & Other Metrics
Beta i0.120.95
Book Value per Share (MRQ) i₹921.88₹173.28

Financial Statements Comparison: Pfizer vs Concord Biotech

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)PFIZERCONCORDBIO
Revenue/Sales i₹6.03B₹2.04B
Cost of Goods Sold i₹2.11B₹451.04M
Gross Profit i₹3.92B₹1.59B
Research & Development iN/AN/A
Operating Income (EBIT) i₹1.96B₹436.22M
EBITDA i₹2.77B₹765.67M
Pre-Tax Income i₹2.60B₹587.32M
Income Tax i₹677.80M₹146.74M
Net Income (Profit) i₹1.92B₹440.58M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)PFIZERCONCORDBIO
Cash & Equivalents i₹4.95B₹9.05M
Total Current Assets i₹35.13B₹11.35B
Total Current Liabilities i₹5.70B₹1.84B
Long-Term Debt i₹676.20M₹6.30M
Total Shareholders Equity i₹42.17B₹18.13B
Retained Earnings i₹24.36BN/A
Property, Plant & Equipment i₹1.72B₹7.94B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)PFIZERCONCORDBIO
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPFIZERCONCORDBIO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i22,26189,767
Average Daily Volume (90 Day) i49,780116,021
Shares Outstanding i45.75M104.62M
Float Shares i15.12M26.36M
% Held by Insiders i0.67%0.75%
% Held by Institutions i0.17%0.14%

Dividend Analysis & Yield Comparison: Pfizer vs Concord Biotech

MetricPFIZERCONCORDBIO
Last 12-Month Dividend i₹70.00₹8.75
Last 12-Month Dividend Yield i1.27%0.44%
3-Year Avg Annual Dividend i₹46.67₹2.92
3-Year Avg Dividend Yield i0.58%0.56%
3-Year Total Dividends i₹140.00₹8.75
Ex-Dividend DateJul 09, 2025Jun 21, 2024